Core Viewpoint - The Shanghai Medicilon Inc. has received approval from its Board of Directors' Compensation and Assessment Committee for its 2025 Restricted Stock Incentive Plan, indicating compliance with relevant laws and regulations [1][4]. Summary by Sections Compliance with Regulations - The company confirms that there are no prohibitive circumstances under the relevant laws and regulations for implementing the stock incentive plan, including the Company Law and Securities Law [2][3]. - The plan's initial grant recipients meet the qualifications set forth in the Company Law, Securities Law, and other relevant regulations [3][4]. Incentive Plan Details - The initial grant recipients are core employees of the company and its subsidiaries, excluding independent directors and supervisors, ensuring compliance with the incentive object conditions [3][4]. - The plan's formulation, review process, and content adhere to the legal requirements, and the granting arrangements do not infringe on the interests of the company and its shareholders [4]. Governance and Objectives - The implementation of the incentive plan is expected to enhance the company's governance structure, attract and retain talent, and align the interests of shareholders, the company, and the core team [4].

Group 1 - The company has proposed an equity incentive plan that includes the allocation of restricted stock to core employees, with a total of 385 individuals receiving 80% of the plan's total equity [1] - The total number of restricted shares to be granted is 1 million shares, which represents 0.74% of the company's total share capital [1] - The plan reserves 20% of the total equity for future allocation, amounting to 200,000 shares [1] Group 2 - The company's board of directors, along with the compensation committee and supervisory board, will provide clear opinions and legal advice regarding the incentive plan [2]

Core Points - The company has established a 2025 Restricted Stock Incentive Plan to enhance corporate governance and attract talent while aligning the interests of shareholders, the company, and core teams [1][2] - The plan aims to ensure the achievement of long-term development strategies and operational goals while safeguarding shareholder interests [1][2] Assessment Objectives - The purpose of the assessment is to strengthen the execution of the incentive plan, quantify specific goals, and promote a scientific, standardized, and institutionalized management of the assessment process [2] - The assessment will objectively and fairly evaluate employee performance and contributions, providing a comprehensive basis for the execution of the incentive plan [2] Assessment Principles - The assessment will adhere to principles of fairness, justice, and transparency, strictly evaluating the incentive objects according to the established guidelines [2] - Assessment indicators will be aligned with the company's medium to long-term development strategy and annual operational goals, as well as the performance, capability, and attitude of the incentive objects [2] Assessment Scope - The assessment applies to all incentive objects defined in the plan, including core employees but excluding independent directors and supervisors [2] - All incentive objects must have signed labor or employment contracts with the company or its subsidiaries during the assessment period [2] Assessment Institutions and Execution - The company's Compensation and Assessment Committee will lead and review the assessment of incentive objects [2] - The Human Resources and Finance Departments will form an assessment team responsible for collecting and providing relevant data, ensuring its authenticity and reliability [2] Performance Assessment Indicators and Standards - The vesting of restricted stocks will depend on both company-level and individual-level assessment results [3] - Company-level performance assessment targets for the fiscal years 2025 and 2026 include specific revenue growth thresholds, with the first vesting period requiring a minimum of 10% revenue growth and the second period requiring 20% [3][4] Assessment Period and Frequency - The assessment period for the restricted stock incentive plan spans the fiscal years 2025 and 2026, with annual assessments conducted for both company-level and individual-level performance [5] Assessment Procedures - The Human Resources and Finance Departments will conduct the assessments under the guidance of the Compensation Committee, maintaining records of the results and submitting a performance assessment report [5] Assessment Results Management - Assessment results will be communicated to the assessed individuals within five working days after the assessment, with provisions for appeals to the Compensation Committee [5] - Records of the assessment results will be archived as confidential documents [5] Additional Provisions - The Compensation Committee is responsible for formulating and revising the assessment guidelines, which will be implemented upon approval by the shareholders' meeting [6]

上海美迪西生物医药股份有限公司 2025 年限制性股票激励计划（草案） 证券简称：美迪西 证券代码：688202 上海美迪西生物医药股份有限公司 二〇二五年八月 上海美迪西生物医药股份有限公司 2025 年限制性股票激励计划（草案） 声明 本公司及全体董事、监事保证本激励计划及其摘要不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 上海美迪西生物医药股份有限公司 2025 年限制性股票激励计划（草案） 特别提示 一、《上海美迪西生物医药股份有限公司 2025 年限制性股票激励计划（草 案）》由上海美迪西生物医药股份有限公司（以下简称"美迪西""公司"或"本 公司"）依据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司 股权激励管理办法》《上海证券交易所科创板股票上市规则》《科创板上市公司 自律监管指南第 4 号——股权激励信息披露》和其他有关法律、行政法规、规范 性文件，以及《公司章程》等有关规定制订。 二、美迪西 2025 年限制性股票激励计划（以下简称"本激励计划"）采取 的激励形式为第二类限制性股票。股票来源为公司从二级市场回购的本公司人民 ...

Core Viewpoint - Shanghai Medicy Bio-Pharmaceutical Co., Ltd. has announced a stock incentive plan involving the issuance of restricted stocks to attract and retain talent, enhance team cohesion, and align the interests of shareholders, the company, and core team members [1][2][3]. Group 1: Stock Incentive Plan Overview - The incentive plan will grant a total of 1 million restricted stocks, with 800,000 stocks (80%) for initial grants and 200,000 stocks (20%) reserved for future allocation [3][4]. - The stocks will be sourced from the company's repurchased A-shares in the secondary market, with a repurchase average price of 31.21 RMB per share [3][4]. - The plan aims to improve corporate governance and establish a long-term incentive mechanism [1][2]. Group 2: Eligibility and Distribution - The incentive plan targets 385 core employees, excluding independent directors and supervisors, with the aim of including foreign employees due to competitive talent demands [5][6]. - The distribution of restricted stocks will be based on performance evaluations, with a maximum of 1% of the total share capital allocated to any individual [4][6]. Group 3: Vesting Conditions and Performance Metrics - The vesting period for the restricted stocks is set for a maximum of 48 months, with specific performance targets for 2025 and 2026, including revenue growth of at least 10% and 20% respectively [14][16]. - The performance evaluation will consider both company-level metrics (revenue and net profit) and individual performance ratings [16][17]. Group 4: Accounting and Financial Impact - The estimated total cost for the incentive plan is projected at 22.57 million RMB, which will be recognized as an expense over the vesting period [24][26]. - The plan is expected to positively influence the company's long-term performance by motivating employees and improving operational efficiency [26].

Market Overview - The medical services sector rose by 3.64% on August 29, with the leading stock being Puris [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Top Gainers in Medical Services - Zenggansi (301257) closed at 43.54, up 20.01% with a trading volume of 64,900 shares and a turnover of 278 million [1] - Haoyuan Pharmaceutical (688131) closed at 68.48, up 13.70% with a trading volume of 189,200 shares and a turnover of 1.256 billion [1] - Bidai Pharmaceutical (688073) closed at 67.11, up 10.43% with a trading volume of 28,300 shares and a turnover of 182 million [1] - Meidi Xi (688202) closed at 64.21, up 8.96% with a trading volume of 124,400 shares and a turnover of 784 million [1] - WuXi AppTec (603259) closed at 103.30, up 7.95% with a trading volume of 1,016,600 shares and a turnover of 10.18 billion [1] Top Losers in Medical Services - Digital Human (835670) closed at 17.54, down 6.20% with a trading volume of 127,200 shares and a turnover of 227 million [2] - Puri Eye Hospital (301239) closed at 40.78, down 4.63% with a trading volume of 49,600 shares and a turnover of 203 million [2] - Yingkang Life (300143) closed at 10.64, down 3.45% with a trading volume of 230,300 shares and a turnover of 250 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 1.259 billion from institutional investors, while retail investors experienced a net outflow of 446 million [2][3] - Major stocks like WuXi AppTec had a net inflow of 1.269 billion from institutional investors, while it faced a net outflow of 741 million from retail investors [3]

Group 1 - The A-share market saw a significant rise in CRO concept stocks, with notable increases in share prices for several companies [1] - Haoyuan Pharmaceutical experienced a rise of over 15%, while Chengdu XianDao and MeidiXi saw increases of over 11% and 10% respectively [1] - Other companies such as Bid Pharma, Boteng Co., and WuXi AppTec also reported gains exceeding 7% [1] Group 2 - The following table summarizes the performance of key CRO stocks, including their percentage increase, total market capitalization, and year-to-date performance [2] - Haoyuan Pharmaceutical: +15.19%, Market Cap: 14.7 billion, YTD: +95.07% - Chengdu XianDao: +11.02%, Market Cap: 10.7 billion, YTD: +116.70% - MeidiXi: +10.54%, Market Cap: 8.75 billion, YTD: +115.91% - Bid Pharma: +8.39%, Market Cap: 5.99 billion, YTD: +36.61% - Boteng Co.: +7.51%, Market Cap: 13.6 billion, YTD: +58.02% - WuXi AppTec: +7.43%, Market Cap: 303.4 billion, YTD: +90.82% - Sunshine Nuohe: +6.32%, Market Cap: 8.46 billion, YTD: +100.86% - Baicheng Pharmaceutical: +4.97%, Market Cap: 6.29 billion, YTD: +51.90% - Kailai Ying: +4.49%, Market Cap: 39 billion, YTD: +43.98% - NuoSiGe: +4.35%, Market Cap: 5.19 billion, YTD: +7.82% [2]

Group 1 - The A-share CRO (Contract Research Organization) sector experienced a significant rally on August 29, with notable stock price increases [1] - Haoyuan Pharmaceutical surged over 14%, while Medices and Chengdu Xian Dao saw increases of over 10% and 9% respectively [1] - Other companies such as Pruis and Boteng Co., along with Inno Laser, also showed positive performance in the market [1]

Core Viewpoint - The innovative pharmaceutical stocks experienced a significant rebound, with Huahai Pharmaceutical and Kangchen Pharmaceutical both hitting the daily limit up, indicating strong market interest and investor confidence in the sector [1] Industry Summary - The National Medical Products Administration of China reported that the country's pharmaceutical industry ranks second globally, with approximately 30% of the world's innovative drugs currently under research [1] - Since the beginning of the 14th Five-Year Plan, a total of 387 pediatric drugs and 147 rare disease drugs have been approved for market, effectively addressing the medication needs of key populations [1] Company Summary - Huahai Pharmaceutical and Kangchen Pharmaceutical both reached the daily limit up, reflecting positive market sentiment towards their stock performance [1] - Other companies such as Puris, Duolai Pharmaceutical, Haoyuan Pharmaceutical, Huana Pharmaceutical, Medisi, Lifang Pharmaceutical, and Guangshengtang also saw stock increases, with some rising over 5% [1]

格隆汇8月28日丨美迪西(688202.SH)发布2025半年度报告，公司上半年实现营业收入5.40亿元，同比增 长3.64%；归母净利润-1289.84万元，上年同期-7023.03万元；扣非归母净利润-2673.04万元，上年同 期-7960.24万元。 ...